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p63, a transcription factor of the p53 gene family, is 
known to play a fundamental role  in the development 
of all the stratified squamous epithelia, including breast. 
The use of two different promoters results in the 
generation of two different isoforms known as TAp63 
and ΔNp63, containing or lacking the trans-activation 
domain. Each isoform can undergo alternative splicing 
thus generating different variants, α, β, γ, δ and ε. Since 
its discovery p63’s physiological role has been 
controversial with some authors supporting a main role 
in maintenance of the stem cell compartment and others 
suggesting that its main role is crucial in driving the 
differentiation program. It is most likely that indeed p63 
exerts both roles with the different variants showing 
different activities, with the  ΔNp63 isoform playing a 
crucial role in  the maintenance of stemness 
(characterizing stem and progenitor cells), while TAp63 
is requested to allow terminal differentiation [1].  
Similarly alterations of expression of this gene have 
been described in cancer where the gene has been 
suggested to play a role either as a tumor suppressor or 
an oncogene. Recent work highlights p63 role in breast 
cancer development, showing that ΔNp63 promotes the 
breast cancer stem cell (CSC) phenotype by fueling Wnt 
and Shh pathways activity [2, 3]. Both Wnt and Shh 
pathways are also crucial for normal mammary stem 
cell development, and therefore this work further 
supports a main role for ΔNp63 in maintaining a stem 
phenotype also in physiological conditions. In our 
recently published study we have further investigated 
the role of both p63 isoforms in breast cancer cells, 
focusing on the mechanisms driving metastatic 
spreading and acquisition of resistance to conventional 
anti-tumor therapies [4]. Our findings show for the first 
time that ΔNp63 positively regulates the PI3K/CD44v6 
pathway. We have previously shown that CD44v6 
expression in colorectal CSCs activates the Wnt/β-
catenin pathway, thus promoting migration and 
metastasis [7]. Now we show that CD44v6+ breast 
cancer cells present a strong activation of the  PI3K 
pathway, and that its inhibition leads to a reduction in 
metastatic potential and viability of CD44v6+ CSCs. 
Moreover by transcriptome analysis we show that 
ΔNp63 increases both tumorigenic and metastatic 
potential of breast cancer cells by activating the 
expression of a plethora  of  genes,  including  PDGFRB  
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and TWIST1. In line with these results, our in vivo 
experiments show that the ΔNp63 overexpressing cells 
are localized at the invasive front of the tumor, in 
proximity of endothelial cells and are therefore more 
exposed to factors released in the tumor  
microenvironment. Indeed we show that exposure of 
breast cancer cells to cytokines such as  HGF, SDF-1 
and OPN increased ΔNp63 as well as CD44v6 
expression levels and activation of the PI3K pathway 
suggesting that the tumor microenvironment supports a 
stem like phenotype by inducing ΔNp63 upregulation. 
We also show that an important consequence of 
increased levels of ΔNp63 is that BCSCs acquire 
resistance to aromatase inhibitors and taxanes used in 
combination with PI3K inhibitors treatments that are 
currently undergoing clinical trials for the treatment of 
both luminal and basal breast cancers.  
In consideration of all the recent findings, it is clear 
how the different isoforms of p63 are capable of 
regulating a large number of target genes involved in 
different steps of breast cancer progression, including 
cell proliferation and metastatic capacity. For this 
reason, it will be crucial in the next future to find a way 
to selectively target ΔNp63 or its downstream master 
regulators, such as PI3K or CD44v6. The inhibition of  
PI3K/CD44v6 axis in combination with current anti-
tumor therapies could be a very promising strategy to 
overcome both primary tumor formation, metastases 
and relapses. 
. 
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